People channel feed

Look­ing to move past an R&D fi­as­co, Ipsen poach­es their new CEO from Sanofi

Ipsen has turned to another Paris-based biopharma company for its next CEO.

Sanofi Pasteur chief David Loew — who’s been leading one of the most advanced efforts to develop vaccines for Covid-19 — is making the journey to Ipsen, 5 months after David Meek jumped ship to run a startup in late-stage development.

Loew arrives as Ipsen works to get back on track with their rare bone disease drug palovarotene, picked up in the $1.3 billion Clementia buyout, which was slammed with a partial hold after researchers observed cases of “early growth plate closure” in patients under the age of 14. But they are pushing ahead with the over-14 crowd after writing down slightly more than half of its initial development.

Pablo Legorreta, founder and CEO of Royalty Pharma AG, speaks at the annual Milken Institute Global Conference in Beverly Hills, California (Patrick T. Fallon/Bloomberg via Getty Images)

Cap­i­tal­iz­ing Pablo: The world’s biggest drug roy­al­ty buy­er is go­ing pub­lic. And the low-key CEO di­vulges a few se­crets along the way

Pablo Legorreta is one of the most influential players in biopharma you likely never heard of.

Over the last 24 years, Legorreta’s Royalty Pharma group has become, by its own reckoning, the biggest buyer of drug royalties in the world. The CEO and founder has bought up a stake in a lengthy list of the world’s biggest drug franchises, spending $18 billion in the process — $2.2 billion last year alone. And he’s become one of the best-paid execs in the industry, reaping $28 million from the cash flow last year while reserving 20% of the cash flow, less expenses, for himself.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 83,100+ biopharma pros reading Endpoints daily — and it's free.

Fabrice Chouraqui, Cellarity CEO-partner (LinkedIn)

Drug de­vel­op­er, Big Phar­ma com­mer­cial ex­ec, now an up­start biotech chief — Fab­rice Chouraqui is ready to try some­thing new as a ‘CEO-part­ner’ at Flag­ship

Fabrice Chouraqui’s career has taken some big twists along his life journey. He got his PharmD at Université Paris Descartes and jumped into the drug development game for a bit. Then he took a sharp turn and went back to school to get his MBA at Insead before returning to pharma on the commercial side.

Twenty years later, after steadily rising through the ranks and journeying the globe to nab a top job as president of US pharma for the Basel-based Novartis, Chouraqui exited in another career switch. And now he’s headed into a hybrid position as a CEO-partner at Flagship, where he’ll take a shot at leading Cellarity — one of the VC’s latest paradigm-changing companies of the groundbreaking model that aspires to deliver a new platform to the world of drug R&D.

Stymied by the pan­dem­ic, Im­munomedic­s' new CEO bows out, tak­ing a mil­lion bucks plus perks as he heads out the vir­tu­al ex­it

Just a little more than a month since taking over as the latest CEO to helm Immunomedics, $IMMU Harout Semerjian is exiting the company after being confronted by “logistical” obstacles thrown up by the pandemic that made it impossible for him to move from London to carry out the job. And he’s getting a little over a million dollars in cash plus perks to grease the skids on the way out.

Word of the changeup arrived right after the market closed Wednesday.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 83,100+ biopharma pros reading Endpoints daily — and it's free.

via Shutterstock

Ex-biotech chief pleads guilty in col­lege ad­mis­sions scan­dal, faces a 10-month prison stretch in plea deal

The ex-CEO of Harmony Biosciences — as well as former board member for Biohaven — has agreed to plead guilty to two counts of mail fraud after getting caught up in the college admissions scandal.

Charged with paying Georgetown University’s former tennis coach more than $50,000 to get his daughter admitted to the university as a new recruit for the team, Bob Repella took the plea deal, which comes with a recommended sentence of 10 months in prison, with a year of supervised release and a $40,000 fine.

An­dreessen Horowitz backs a new mol­e­cule builder from UCLA equipped with the lat­est in con­ver­gence tech. And he’s aim­ing big

Sri Kosuri has spent years at a scientific crossroads, watching the rapidly accelerating work on synthetic biology, big data and genomics. The MIT grad spent time working as a staff scientist with George Church at the Wyss Institute. And he kept at it as a professor in chemistry at UCLA.

Now, Kosuri’s taken a leave of absence after bagging a $30 million investment from Andreessen Horowitz to see if he can take these convergent technologies in polypharmacology and create a powerful new machine for drug discovery. The upstart biotech is called Octant. And Kosuri’s shooting for something groundbreaking in the toughest fields he can find.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 83,100+ biopharma pros reading Endpoints daily — and it's free.

Iya Khalil (Multiple Myeloma Research Foundation via YouTube)

No­var­tis taps Iya Khalil, physi­cist co-founder of GNS Health­care, to lead AI In­no­va­tion Cen­ter

At the turn of the millennium, finishing up her PhD in theoretical physics, Iya Khalil found the career paths in front of her wanting. Academic postings were tough to get, but she couldn’t envision applying all she’s learned to predict stocks on Wall Streets, as some of her contemporaries did.

She was working on models of two-dimensional electron gas, a topic in solid-state physics, when she met Colin Hill, the fellow Cornell physicist with whom she would later start a company named Gene Network Sciences.

President Donald Trump, left, listens as Moncef Slaoui, a former GlaxoSmithKline executive, speaks about the coronavirus in the Rose Garden of the White House, Friday, May 15, 2020, in Washington. (AP Photo/Alex Brandon)

Mon­cef Slaoui piv­ots from Mod­er­na's board to the helm of Pro­ject Warp Speed. His task: Overnight suc­cess

Moncef Slaoui stepped off Moderna’s board of directors on Friday and pivoted straight into the high profile role heading the Trump administration’s Project Warp Speed, where he’ll be in charge of accelerating Moderna’s — and others — vaccines to a rapid release for a pandemic weary world.

The news became official mid-day Friday after numerous reports earlier that he had been picked off the short list of candidates.

Rick Bright arrives to testify before the House Energy and Commerce Subcommittee on Health on May 14, 2020, in Washington, DC. (Greg Nash, POOL/AFP via Getty Images)

Rick Bright de­tails mis­man­aged pan­dem­ic re­sponse, warns of drugs, vac­cine sup­ply prob­lems down the road; HHS push­es back

In wide-ranging congressional testimony, the ousted head of an agency at the center of the federal government’s Covid-19 vaccine and treatment response criticized the Trump administration for a slow-footed federal response that could resound throughout the course of the pandemic.

“I believe we could have done better,” Rick Bright, former chief of the Biomedical Advanced Research and Development Authority (BARDA), told a House subcommittee. “We don’t have the right leadership for this response and we don’t have the right plan for this response.”

Incoming BIO CEO Michelle McMurry-Heath (BIO)

BIO gets a new chief lob­by­ist to face off against the grow­ing ranks of crit­ics in Con­gress

BIO has selected its next CEO to succeed James Greenwood as one of biotech’s top lobbyists. And she comes with a dream résumé that rings all the right bells — except for one.

She’s never served in Congress as an elected official.

Harvard-educated with an MD from Duke, Michelle McMurry-Heath got the job after spending more than 5 years largely centered on regulatory work for J&J, specializing in devices. That gives her plenty of Big Pharma insight into the FDA that will help in influencing a key government agency. Even better, she jumped to industry from the FDA, where she was associate director for science, center for devices and radiological health.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 83,100+ biopharma pros reading Endpoints daily — and it's free.